Position in TNGX
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$6,010,360
+$5,720,199 QoQ
Shares Held
192,270
-9.2% QoQ
Ownership
0.114%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#94
of 247 holders
Holding Since
Sep 2021
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TNGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names. TNGX ranks #16 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
126,005 | $33,608,053 | |
| 2 | CYTK |
Cytokinetics Inc
|
239,728 | $20,422,428 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
288,233 | $16,492,692 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
386,183 | $14,393,040 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,596 | $14,089,509 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
334,854 | $11,180,775 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
347,898 | $11,111,862 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
353,226 | $10,487,279 |
All Filings in TNGX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,010,360 | 192,270 | Shares | Sole | 2026-08-03 | |
| 2025-03-31 | $290,161 | 211,797 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $886,990 | 287,052 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $1,097,835 | 142,576 | Shares | Sole | 2024-11-14 | |
| 2024-03-31 | $104,585 | 13,172 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $219,403 | 22,162 | Shares | Sole | 2024-02-14 | |
| 2022-12-31 | $2,101,535 | 289,867 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $1,464,822 | 404,647 | Shares | Sole | 2022-11-14 | |
| 2021-09-30 | $535,495 | 41,415 | Shares | Sole | 2021-11-15 | |
| No filing history on record for this holder in this stock. | ||||||